Houston, TX 的 黑色素瘤 臨床試驗
59 項針對 黑色素瘤 的研究正在 Houston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- UT MD Anderson Cancer Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study of BI 3810944 in Patients With Advanced Cancer
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
招募中3 期
- The University of Texas MD Anderson Cancer Center, Houston
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
招募中2 期
- MD Anderson Cancer Center, Houston
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
招募中2 期
- UT MD Anderson Cancer Center, Houston
Pan-tumor MRD Study
招募中觀察性研究
- Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
Intratumoral N17350 in Advanced Solid Tumors
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- MD Anderson Cancer Center, Houston
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
招募中1 期
- M D Anderson Cancer Center, Houston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
招募中2 期
- Local Institution - 0085, Houston
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
招募中1/2 期
- University of Texas-MD Anderson, Houston
- Lumi Research, Houston
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
招募中1 期
- MD Anderson, Houston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
招募中1/2 期
- The University of Texas M. D. Anderson Cancer Center, Houston
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
招募中1 期
- MD Anderson Cancer Center, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Project: Every Child for Younger Patients With Cancer
招募中觀察性研究
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
招募中觀察性研究
- M D Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
招募中1/2 期
- Research Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
招募中1/2 期
- Houston Methodist Hospital, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- The University of Texas, MD Anderson Cancer Center, Houston
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
招募中2 期
- M D Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
招募中1/2 期
- M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
招募中2 期
- M D Anderson Cancer Center, Houston
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
招募中2 期
- M D Anderson Cancer Center, Houston
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
招募中1 期
- M D Anderson Cancer Center, Houston
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
招募中
- M D Anderson Cancer Center, Houston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
招募中2 期
- USA12-0, Houston
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
招募中
- M D Anderson Cancer Center, Houston
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
招募中觀察性研究
- M D Anderson Cancer Center, Houston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
招募中1/2 期
- University of Texas MD Anderson Cancer Center, Houston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
招募中3 期
- Retina Consultants of Texas - (Houston), Houston
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
招募中觀察性研究
- M D Anderson Cancer Center, Houston
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
招募中2 期
- M D Anderson Cancer Center, Houston
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
招募中1 期
- MD Anderson Cancer Center, Houston
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
招募中觀察性研究
- M D Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
招募中
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Study of VET3-TGI in Patients With Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
招募中2/3 期
- The University Of Texas Md Anderson Cancer Center, Houston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
招募中3 期
- Houston Methodist Hospital/Houston Methodist Cancer Center, Houston
ACTengine® IMA203 Combined With mRNA-4203
招募中1 期
- MD Anderson Cancer Center, Houston
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
招募中3 期
- The University of Texas M.D. Anderson Cancer Center, Houston
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Houston
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
招募中1/2 期
- MD Anderson Cancer Center, Houston
BostonGene and Exigent Genomic INsight Study
招募中觀察性研究
- Oncology Consultants, Houston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
招募中1/2 期
- Oncology Consultants, P.A., Houston
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of IBI363 in Subjects with Advanced Solid Malignancies
招募中2 期
- MD Anderson Cancer Center-University of Texas, Houston
- Oncology Consultants P.A., Houston
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
招募中
- The University of Texas MD Anderson Cancer Center, Houston
其他城市的 黑色素瘤 試驗
- New York City, NY38 項研究
- Los Angeles, CA34 項研究
- Nashville, TN33 項研究
- Pittsburgh, PA31 項研究
- Boston, MA26 項研究
- Philadelphia, PA23 項研究
- San Francisco, CA22 項研究
- Atlanta, GA21 項研究
- Durham, NC21 項研究
- St. Louis, MO21 項研究
- Columbus, OH21 項研究
- Salt Lake City, UT21 項研究
Houston 的其他研究
- 非小細胞肺癌145 項研究
- 乳癌126 項研究
- 癌症（所有類型）121 項研究
- 轉移性癌症104 項研究
- 大腸直腸癌102 項研究
- 卵巢癌89 項研究
- 急性髓系白血病85 項研究
- 肺癌78 項研究
- 前列腺癌76 項研究
- 子宮內膜癌68 項研究
- 胰臟癌61 項研究
- 頭頸部鱗狀細胞癌47 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。